Crossref
New Developments in Antipsychotics: Xanomeline–Trospium as Monotherapy or as Adjuvant
Psychopharmakotherapie · 2025 · 32 (7) · 1112-1116
DOI: 10.52778/ppt20250037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmakotherapie, 2025. Verfasst von Georgios Schoretsanitis und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Schoretsanitis, G., Seifritz, E., & Paulzen, M. (2025). New Developments in Antipsychotics: Xanomeline–Trospium as Monotherapy or as Adjuvant. Psychopharmakotherapie, 32(7), 1112-1116. https://doi.org/10.52778/ppt20250037
Vancouver
Schoretsanitis G, Seifritz E, Paulzen M. New Developments in Antipsychotics: Xanomeline–Trospium as Monotherapy or as Adjuvant. Psychopharmakotherapie. 2025;32(7):1112-1116. doi:10.52778/ppt20250037
BibTeX
@article{Schoretsanitis2025,
author = {Schoretsanitis, Georgios and Seifritz, Erich and Paulzen, Michael},
title = {New Developments in Antipsychotics: Xanomeline–Trospium as Monotherapy or as Adjuvant},
journal = {Psychopharmakotherapie},
year = {2025},
volume = {32},
number = {7},
pages = {1112--1116},
doi = {10.52778/ppt20250037}
}
EUVIMED